Dyno Therapeutics is reshaping the gene therapy landscape with AI-powered AAV vectors

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

• Industry

  • AI & Machine Learning
  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2021

• Founders

  • Eric Kelsic
  • Alan Crane
  • Sam Simai
  • Adrian Veres
  • George Church
  • Tomas Bjorklund

  LUX Partners

  • Zavain Dar

• Latest Tweets

  • You can watch our symposium session here: https://t.co/tkD4Hddy1w@Dyno_Tx - 09:14 PM May 13th
  • Tune in for Dyno's #ASGCT21 industry symposium later today! https://t.co/17IXdol40X@Dyno_Tx - 07:26 PM May 13th
  • #ASGCT21 is here! We're presenting on continued advancements of our CapsidMap platform for #AAV #genetherapy vecto… https://t.co/mmvTtlmKXh@Dyno_Tx - 01:04 PM May 11th